ImmuneSensor Therapeutics Granted New U.S. Patent for its Oral cGAS Inhibitors
17 sept. 2024 08h00 HE
|
ImmuneSensor Therapeutics
Composition and methods patent granted claims covering compounds for treating broad range of inflammatory and autoimmune diseases and built on foundational intellectual property for the discovery of...
US Rheumatologists Believe Biogen’s Litifilimab Is the Leading SLE Pipeline Asset Poised to Offer Improvement Over Benlysta and Saphnelo Based on Clinical Trial Data
12 sept. 2024 16h36 HE
|
Spherix Global Insights
EXTON, PA, Sept. 12, 2024 (GLOBE NEWSWIRE) -- The systemic lupus erythematosus (SLE) advanced treatment landscape is poised for evolution, with multiple new therapies in development to treat this...
ImmuneSensor Therapeutics Receives Clearance from Australian Regulators to Initiate a First-in-Human Phase 1 Clinical Trial of cGAS inhibitor Drug Candidate, IMSB301
19 août 2024 08h00 HE
|
ImmuneSensor Therapeutics
Novel, oral IMSB301 is a potent cGAS inhibitor designed to block signaling through a central pathway that drives diverse inflammatory and autoimmune diseases Company expects to initiate its Phase 1...
Rheumatologists' Aggressive Approach to SLE Treatment Targets Specific Patient Types with Biologics
13 juin 2024 10h16 HE
|
Spherix Global Insights
EXTON, PA, June 13, 2024 (GLOBE NEWSWIRE) -- Since 2021, the treatment options for systemic lupus erythematosus (SLE) and lupus nephritis (LN) have expanded with the approval of AstraZeneca’s...
GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)
21 mai 2024 08h35 HE
|
GRI Bio, Inc.
Data presented at the 14th International Congress on Autoimmunity Encouraging preclinical data observed to date on par with OFEV® (nintedanib), a leading tyrosine kinase inhibitor with 2025...
Autolus Therapeutics to host virtual event to discuss the company’s obe-cel program in systemic lupus erythematosus
17 oct. 2023 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics to host virtual event to discuss the company’s obe-cel program in systemic lupus erythematosus
In a Push to Limit Use of Glucocorticoids, US and EU5 Rheumatologists are Increasingly Turning to GSK’s Benlysta and AstraZeneca’s Saphnelo for the Treatment of Moderate-to-Severe Systemic Lupus Erythematosus, According to Spherix Global In
04 oct. 2023 03h00 HE
|
Spherix Global Insights
Exton, Pennsylvania, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Prior to the initial approval of Benlysta in 2011, systemic lupus erythematosus (SLE) patients and prescribers had limited options for the...
GRI Bio Presents Encouraging Preclinical Data Indicating Oral Administration of GRI-0803 Inhibited Lupus Nephritis and Significantly Improved Overall Survival in Animal Models
07 août 2023 08h35 HE
|
GRI Bio, Inc.
Data presented at The Autoimmunity Conference hosted by the Federation of American Societies for Experimental Biology (FASEB) GRI-0803 in development with an initial focus on the treatment...
Systemic Lupus Erythematosus Market Size Growing at 7% CAGR, Set to Reach USD 3,517 Million By 2030
01 mars 2023 10h00 HE
|
Acumen Research and Consulting
LOS ANGELES, March 01, 2023 (GLOBE NEWSWIRE) -- The Global Systemic Lupus Erythematosus Market Size accounted for USD 1,951 Million in 2021 and is estimated to achieve a market size of USD 3,517...
The New England Journal of Medicine Publishes Second Manuscript Reporting Positive Phase 2 Results for Biogen’s Litifilimab (BIIB059) in Lupus
07 sept. 2022 17h45 HE
|
Biogen Inc.
Part A results from the two-part Phase 2 LILAC study show litifilimab significantly reduced disease activity based on active joint count in people with systemic lupus erythematosus (SLE) compared to...